Skip to content

The future of immune checkpoint therapy

Padmanee Sharma, James Patrick Allison

Science · 2015 · 4,954 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56–61. https://doi.org/10.1126/science.aaa8172

In text: (Sharma & Allison, 2015)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.

  1. Integrated analysis of multimodal single-cell data2021
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
  3. Control of Regulatory T Cell Development by the Transcription Factor Foxp32003
  4. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer2012
  5. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.1986

Metadata from OpenAlex (CC0). Citations are generated from the published record.